Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dingdang Health Technology Group's earnings before interest and taxes (EBIT) for the
six
months ended in Jun. 2026 was HK$-60 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-37 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Dingdang Health Technology Group's annualizedROC % for the quarter that ended in Jun. 2026 was 1.97%.
Dingdang Health Technology Group's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -29.55%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Dingdang Health Technology Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -74.82%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dingdang Health Technology Group EBIT Related Terms
Dingdang Health Technology Group EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Dingdang Health Technology Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dingdang Health Technology Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dingdang Health Technology Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dingdang Health Technology Group's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dingdang Health Technology Group (HKSE:09886) has a EBIT of HK$-37 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dingdang Health Technology Group.
Is Dingdang Health Technology Group's EBIT too high?
Dingdang Health Technology Group's current EBIT is HK$-37 Mil. Overall, Dingdang Health Technology Group has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dingdang Health Technology Group's EBIT compare to VEEV and BTSG?
Dingdang Health Technology Group's EBIT of HK$-37 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dingdang Health Technology Group. Dingdang Health Technology Group's current EBIT is HK$-37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dingdang Health Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Dingdang Health Technology Group (HKSE:09886) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.44, compared to a current price of HK$0.81 — trading 43.8% below its estimated fair value. The current EBIT is HK$-37 Mil. Dingdang Health Technology Group's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dingdang Health Technology Group (HKSE:09886), the current EBIT is HK$-37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dingdang Health Technology Group (HKSE:09886) Overvalued in 2026?
Based on GuruFocus' analysis, Dingdang Health Technology Group stock appears to be undervalued.
The current stock price of HK$0.81 is trading 43.8% below its estimated GF Value™ of HK$1.44.
GuruFocus considers Dingdang Health Technology Group to be Possible Value Trap.
Key valuation signals for HKSE:09886:
EBIT: HK$-37 Mil
GF Value™: HK$1.44 vs. price of HK$0.81 (43.8% below fair value)
No single metric tells the full story. See the HKSE:09886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dingdang Health Technology Group Ltd is an investment holding company and its subsidiaries are principally engaged in the provision of pharmaceutical and healthcare business in the PRC. It is transforming and reshaping China's healthcare industry by pioneering on-demand pharmaceutical retail and medical consultation, with online-to-offline solutions. All of the company's revenue is generated from the PRC.
68GF Score
Get the complete analysis for HKSE:09886
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09886 has been successfully added to your 
